

Date: 04/11/2021

FREEDOM OF INFORMATION REQUEST - Ref: FOI/015908 – Cancer treatment (lung)

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

Afatinib 2
Alectinib 1
Atezolizumab monotherapy 1
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 0
Bevacizumab 0
Brigatinib 0
Ceritinib 0
Crizotinib 0
Dacomitinib 0
Dabrafenib with Trametinib 0
Docetaxel monotherapy 0
Durvalumab 0
Erlotinib 0
Gefitinib 1
Gemcitabine 3
Nintedanib with Docetaxel 1
Nivolumab 0
Osimertinib 3
Paclitaxel 0
Pembrolizumab monotherapy 12
Pembrolizumab chemo in combination 6
Pemetrexed with Carboplatin 8
Pemetrexed with Cisplatin 0
Vinorelbine and cisplatin/carboplatin 1
Any other active systemic anti-cancer therapy (SACT) 0
Palliative care only 0

Q2. Could you please provide the total number of patients treated with any systemic anti-cancer therapy (SACT) in the last three months for:

Total non-small cell lung cancer (NSCLC) 39
Squamous non-small cell lung cancer (Sq NSCLC) 24
Non-squamous non-small cell lung cancer (Non-Sq NSCLC) 12

Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part? -
Response is the same as your previous request